Erasca: Potential differentiation opportunity in large market for RAS mutated tumors, first coverage (Goldman Sachs)
Goldman Sachs covers clinical-stage precision oncology company Erasca (ERAS.US) for the first time.
Goldman Sachs covers clinical-stage precision oncology company Erasca (ERAS.US) for the first time. Its core pipeline is pan-RAS molecular gel ERAS-0015 and pan-KRAS inhibitor ERAS-4001. The report believes that compared with competing products, ERAS-0015 has an advantage in tolerability while having comparable efficacy, which is crucial in the pursuit of combined drug treatment for tumors. Goldman Sachs predicts peak sales of ERAS-0015 could reach $8.7 billion. The market's focus on this track is whether the drug can eventually become "best-in-class", and Erasca's early data (especially safety) provide a preliminary basis for differentiation. Future data readouts will be key to validating its market position. One-sentence conclusion: Erasca is expected to occupy a place in the huge RAS mutated tumor market with the potential safety advantages of its pipeline, but its clinical potential still needs to be verified by subsequent key data. Positive/negative: Positive for Erasca (ERAS.US). As a pre-revenue biotech company, its stock price is highly sensitive to clinical data. The current valuation incorporates the market’s high expectations for the pan-RAS track, but has not yet fully factored in the differentiated advantages of ERAS-0015. Catalysts: 1) 2H26: ERAS-4001’s preliminary safety and efficacy data; 2) 1H27: ERAS-0015’s clinical data for single-agent expansion and combination therapy will be the biggest stock price catalyst; 3) Competitors (such as Revolution Medicines)’s clinical progress and data releases will affect the market’s overall sentiment on the track.